Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.

@article{OMeara2012MineralocorticoidRA,
  title={Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.},
  author={Eileen O'Meara and Paul Khairy and Malorie Chabot Blanchet and Simon De Denus and Ole Dyg Pedersen and Sylvie Levesque and Mario R Talajic and Anique Ducharme and Michel White and Normand Racine and Jean Lucien Rouleau and Jean-Claude Tardif and Denis Roy},
  journal={Circulation. Heart failure},
  year={2012},
  volume={5 5},
  pages={586-93}
}
BACKGROUND Patients with heart failure (HF) and atrial fibrillation (AF) may differ from the larger HF population with respect to comorbidities, including renal impairment and overall prognosis. Associated cardiorenal interactions may mitigate the effects of pharmacological agents. Our primary objective was to assess the impact of mineralocorticoid receptor antagonists on cardiovascular mortality in patients with AF and HF enrolled in the Atrial Fibrillation and Congestive Heart Failure (AF-CHF… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS
10 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…